Get the Stockscreener App
0.101
21.52%
-0.109
After Hours:
.10
-0.001
-0.99%
Bio Path Holdings Inc stock is traded at $0.101, with a volume of 9,215.
It is down -21.52% in the last 24 hours and down -80.61% over the past month.
See More
Previous Close:
$0.21
Open:
$0.101
24h Volume:
9,215
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-16.08M
P/E Ratio:
-0.00293
EPS:
-34.43
Net Cash Flow:
$-11.54M
1W Performance:
-21.52%
1M Performance:
-80.61%
6M Performance:
-86.27%
1Y Performance:
-97.18%
1-Day Range:
$0.101
$0.1246
1-Week Range:
$0.101
$0.1246
52-Week Range:
$0.101
$0.1246
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.101 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Initiated | ROTH Capital | Buy |
| Nov-13-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Apr-18-16 | Initiated | Rodman & Renshaw | Buy |
| Jun-02-14 | Resumed | Maxim Group | Buy |
| May-09-14 | Initiated | Maxim Group | Buy |
View All
Bio Path Holdings Inc Stock (BPTH) Latest News
Tevogen Bio Holdings Inc. stock trend outlook and recovery pathTrade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Roth Capital Lowers Bio-Path (BPTH) PT to $2 Amidst Pipeline Updates, Liquidity Concerns - MSN
North American Morning Briefing : Stock Futures -2- - MarketScreener
Third Harmonic Bio Inc. stock trend outlook and recovery pathQuarterly Investment Review & Weekly High Potential Alerts - Newser
FGFR Inhibitors Market Set to Surge by 2034 as Targeted Cancer Therapies Transform Treatment Paradigms | DelveInsight - The Malaysian Reserve
Tevogen Bio Holdings and the Path to Revenue by 2026: A Strategic Assessment of Risk, Innovation, and Capital Efficiency - AInvest
Bio-Path: Q2 Earnings Snapshot - Stamford Advocate
Bio-Path Holdings: Navigating Financial Turbulence with Promising RNAi Innovation - AInvest
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
Korro Bio Inc. stock trend outlook and recovery pathJuly 2025 Levels & Technical Entry and Exit Tips - Newser
What’s the recovery path for long term holders of Palisade Bio Inc.2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Bio-Path (BPTH) Projected to Post Earnings on Thursday - Defense World
Bio-Path Holdings dismisses Ernst & Young as auditor, seeks new firm - Investing.com Nigeria
Bio-Path Holdings dismisses Ernst & Young as auditor, seeks new firm By Investing.com - Investing.com South Africa
What’s the recovery path for long term holders of CERo Therapeutics Holdings Inc.High Reward Investment Strategy for Beginners - Newser
Forge Global Holdings Inc. stock trend outlook and recovery pathFree Reliable Chart-Based Trade Entries - Newser
Universal Corporation stock trend outlook and recovery pathFast Return Equity Forecast With Logic - Newser
Marginal Zone Lymphoma Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail
Vitesse Energy Reports Strong Q2 2025 Results and Strategic Advances - The Globe and Mail
Marginal Zone Lymphoma Pipeline Outlook Report 2025: Key 50+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn
What’s the recovery path for long term holders of INmune Bio Inc.Risk-Managed Swing Setup and Signal Analysis - Newser
What’s the recovery path for long term holders of Q2 Holdings Inc.Buy Zone Strategy with Pattern Recognition - Newser
Adicet Bio Inc. stock trend outlook and recovery pathMomentum Trading Guide with Safety Limits - Newser
What’s the recovery path for long term holders of Argo Group International Holdings Inc.Asset Safety Selection Using Quantitative Analysis - Newser
Tevogen Bio's AI-Driven Drug Discovery: A Strategic Pathway to Disrupting Biopharma and Delivering Shareholder Value - AInvest
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update - Defense World
China SXT Pharmaceuticals Restructures Share Classes to Enhance Control - The Globe and Mail
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail
TOPAZ REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS DEMONSTRATING STRONG ROYALTY AND INFRASTRUCTURE GROWTH - The Globe and Mail
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn
Antisense & RNAi Therapeutics Market Outlook 2025-2033: - GlobeNewswire
The Zacks Analyst Blog Highlights Meta Platforms, Alphabet, Microsoft and Tesla - The Globe and Mail
Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033 - Yahoo Finance
Tucows Announces Timing for Q2 2025 Financial Results News Release and Management Commentary - The Globe and Mail
Meta Platforms Is Helping Power This 6%-Yielding Dividend Stock's Continued Growth - The Globe and Mail
Google's AI push pays off with solid second quarter, but doubts about company's future persist - The Globe and Mail
Avino Silver & Gold Mines Reports Strong Q2 Production and Advances Growth Strategy - The Globe and Mail
Tevogen Bio Holdings Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
What analysts say about Tevogen Bio Holdings Inc. stockFree Predictions - jammulinksnews.com
Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire
Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Bio Path Holdings Inc Stock (BPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Cap:
|
Volume (24h):